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Abstract  
We aimed to detect the validity of serum ATX as a diagnostic marker for liver fibrosis. Forty-eight 
males and 16 females were enrolled in the current study. Their ages ranged from 29-57 years with 
mean of 45.09, all were chronically HCV infected. Laboratory assessment was done for all subjects 
in form of complete blood picture; liver function test; lipid profile and serum detection of ATX. 
Patients were grouped according to the stage of fibrosis into group 1: fibrosis score 0, 1, 2, 3; group 
2: fibrosis score: 4, 5, 6.The mean values of ATX in all studied patients with chronic HCV infection 
was 63.02 ± 36.29 while that of healthy controls was 65.31 ± 12.24 without any significant 
difference. Surprisingly, mean values of ATX were higher among patients with group 1 but it did not 
reach the significant level. In each group of them, the differences between mean values of ATX 
among different grades of liver fibrosis were insignificant. It was also noticed that the mean values 
of ATX were higher among men than in women .It was concluded that Autotoxin might not be used 
as a useful diagnostic marker for liver fibrosis in Egyptian chronic HCV patients. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 The published Egyptian Demographic Health 
Survey (EDHS) in 2009 was a national probability 
sample of the resident Egyptian population. This 
report estimated an overall anti-HCV antibody 
prevalence of 14.7 % [1].The major conclusion of 
Miller and Abu-Raddad,  study is that the incidence of 
HCV in Egypt seems to be continuing at a rate of 
≈6.9/1,000 persons per year, indicative of possibly 
ongoing hyper epidemic transmission [2]. 
 Chronic hepatitis C is a slowly progressive 
inflammatory disease that can lead to cirrhosis with all 
its complications. Hepatic schistosomiasis in Egypt is 
commonly associated with HCV infection. Concurrent 
infection results in much more severe liver fibrosis 
than that seen in either disease alone. The prognosis 
of chronic liver disease depends on the progression of 
liver fibrosis. Liver biopsy is recommended as the gold 
standard method for determining fibrosis stage, 
prognosis and therapeutic indications in patients with 
chronic liver disease. However, liver biopsy is an 
invasive procedure associated with a risk of potentially 
serious complications [3]. Approximately 1–3% of 
patients require hospitalization for complications, and 
a quarter of them report pain after percutaneous liver 
biopsy. The diagnostic accuracy of liver biopsy for 
assessing liver fibrosis is influenced by the quality of 
the biopsy samples. In addition, there are several 
absolute or relative contraindications to liver biopsy, 
including severe coagulopathy. Among the possible 
alternatives, imaging is informative mainly for cirrhosis 
but not for lesser stages of fibrosis. In addition, it is 
nonquantitative and thus cannot track progression. A 
safe and non-invasive alternative to liver biopsy is 
therefore needed for assessing liver fibrosis in daily 
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clinical practice [4]. Therefore, research has focused 
on the evaluation of noninvasive methods for the 
assessment of liver fibrosis. . Few serum markers 
such as hyaluronic acid, ferritin, vascular endothelial 
growth factor and soluble interleukin-2 receptor (sIL-
2R) have been reported to be useful in detecting 
fibrosis in liver disease [5, 6]. 
 A previous study indicated that serum ATX 
level was significantly correlated with liver fibrosis 
stage and liver stiffness value [7]. Then, the 
performance of serum ATX level in the prediction of 
cirrhosis was better than serum hyaluronic acid and 
APRI. Autotaxin (ATX), a tumor cell motility-
stimulating factor, regulates the blood concentrations 
of lysophosphatidic acid (LPA), an important and 
multi-functional bioactive lipid, through its 
lysophospholipase D activity (lysoPLD). The 
introduction of ATX measurements into clinical 
laboratory testing is urgently needed. 
 Autotaxin (ENPP-2) is a 125 kDa secreted 
glycoprotein member of the nucleotide 
pyrophosphatase/phosphodiesterase (family of 
enzymes) that was first identified as a motility 
stimulating factor in melanoma cells [8]. It is an 
extracellular lysophospholipase D that regulates the 
blood concentrations of lysophosphatidic acid (LPA), 
an important and multi-functional bioactive lipid from 
lysophosphatidylcholine (LPC). Both ATX and LPA 
have been shown to be involved in many cancers. 
However, the functional role of ATX and the regulation 
of ATX expression in human hepatocellular carcinoma 
(HCC) remain elusive [9]. ENPP-2 is normally widely 
expressed. It is upregulated in melanoma, 
glioblastoma, breast and lung carcinoma, follicular 
lymphoma and other cancers, promoting 
inflammation, proliferation, migration and 
angiogenesis, and is a potential target for treatment 
[10]. 
 ENPP-2 stimulates tumor cell motility and 
enhances invasion and metastasis. ENPP-2 
expression is elevated in reactive astrocytes adjacent 
to sites of neurotrauma, and in rheumatoid arthritis 
synoviocytes, Alzheimer’s disease frontal cortex, and 
multiple sclerosis cerebrospinal fluids. It is thought to 
play a role in neuropathic pain [11]. Investigations to 
clarify the significance of ATX and LPA in liver fibrosis 
found that plasma LPA and serum ATX activity 
increased in patients with chronic hepatitis C [12]. A 
strong correlation was observed between plasma LPA 
and serum ATX activity. Furthermore, plasma LPA 
and serum ATX activity were correlated with blood 
markers for liver fibrosis, such as serum hyaluronate 
and platelet counts. Plasma LPA and serum ATX 
activity increased in association with liver fibrosis 
stage histologically in these patients [13]. Because 
serum ATX activity and plasma LPA are well 
correlated with liver fibrosis stage histologically, both 
of these parameters merit consideration as novel 
markers of fibrosis [13]. 
 The aim of this study is to detect validity of 
serum ATX as non-invasive diagnostic biomarker in 
the assessment of the liver fibrosis and moreover, to 
evaluate whether their serum levels are  correlated  
with the histological severity of the related liver 
biopsies. 
 
Patients and Methods 
 Patients 
 The study was conducted on 68 patients, 57 
men and 11 women with documented chronic HCV 
infection, recruited from National Liver And Tropical 
Diseases Institute, Cairo. Chronic HCV diagnosis was 
based on elevated serum transaminase levels for at 
least six months and positive HCV antibody by the 
second-generation enzyme-linked immunosorbent 
assay and confirmed by detection of circulating HCV 
RNA using polymerase chain reaction (PCR). A liver 
biopsy specimen was taken from every patient. The 
study also included 20 healthy subjects, age and sex 
matched with the patients, as a control group. All 
controls were negative after anti HCV Ab screening 
test. Patients were initiated on treatment with 
subcutaneous pegylated interferon alfa-2a (180 
lg/week) plus oral ribavirin (1000 or 1200 mg/day). 
 Any patients with history of renal disorder, 
recent history of cardiovascular disease or patients 
with hepatitis B infection or human immunodeficiency 
virus infection, autoimmune or metabolic liver 
diseases, diabetes mellitus, patients with body mass 
index (BMI) ≥30 kg/m
2
, patients not eligible for 
interferon therapy were excluded from the study. In 
addition, we excluded patients who were previously 
treated by any drug that may affect the results. 
 
 Sample Collection 
 After obtaining informed verbal consent, ten-
ml fasting blood samples collected in dry clean plastic 
tubes from both controls and patients. The blood were 
allowed to clot and sera were separated by 
centrifugation for 10 min at 3000 r.p.m using 
refrigerated centrifugation, divided into several 
aliquots and processed after conservation at -20 ˚C 
until assayed. Samples confirmed to be collected 
without hemolysis. Major laboratory parameters, 
including blood sedimentation rate, liver and renal 
function tests, blood cell counts; random blood sugar, 
were evaluated at the same time points for all 
participants to exclude any organic disease or 
inflammation. 
 Sera from controls and patients subjected to 
the following investigations: 
 1. Complete blood picture. 
 2. Liver function tests including: Serum 
bilirubin level measured by using the commercially 
available kit from Bio-Merieux Company, France [14]. 
Ezzat et al. Validity of Autotaxin as a Novel Diagnostic Marker for Liver Fibrosis 
______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
OA Maced J Med Sci. 2013 Dec 15; 1(1):21-26.                                                                                                                                                                               23 
 
 3. ALT, AST and Gamma glutamyl 
transferase  measured by using the method 
recommended by the committee on enzymes of the 
Scandinavian Society for Clinical Chemistry and 
Clinical physiology, 1974 [15]. The test performed 
using commercially available kit from Boehringer-
Mannhiem Company, Germany. 
 4. Cholesterol, triglycerides and Albumin.  
 5. Quantitative determination of Autotaxin was 
performed with commercially available Enzyme 
Immunoassay Kit [16]. 
  
 Principle of Autotaxin assay 
 This assay employs the quantitative sandwich 
enzyme immunoassay technique. A monoclonal 
antibody specific for ENPP-2 has been pre-coated 
onto a microplate. Standards and samples are 
pipetted into the wells and any ENPP-2 present is 
bound by the immobilized antibody. After washing 
away any unbound substances, an enzyme-linked 
polyclonal antibody specific for ENPP-2 is added to 
the wells. Following a wash to remove any unbound 
antibody-enzyme reagent, a substrate solution is 
added to the wells and color develops in proportion to 
the amount of ENPP-2 bound in the initial step. The 
color development is stopped and the intensity of the 
color is measured [16]. 
 
 Histological evaluation 
 Liver biopsy was obtained from all patients 
under ultrasound guidance. Biopsies were stained 
with hematoxylin and eosin and liver specific stains 
including van Giesonand Masson’s Trichrome. All 
biopsies were evaluated by the same pathologist 
blinded to the clinical and laboratory criteria. Grading 
for the degree of necroinflammatory activity and 
staging for the extent of fibrosis were done according 
to the criteria of Ishak et al [17]. Patients were 
grouped according to the stage of fibrosis into group 
1: fibrosis score 0, 1, 2, 3; group 2: fibrosis score: 4, 
5,6. This study was carried out in accordance with the 
ethical guidelines.  Informed consent from the patients 
was obtained for the use of the serum samples. 
 
 Statistical analysis 
 Data were presented as mean and standard 
deviation (SD) and percentage. The data were 
analyzed by SPSS version 14 (SPSS Inc., Chicago, 
IL, USA). The following tests of significance were 
used: t-test between means to analyze differences 
between means Differences between nominal 
variables were analyzed by X
2
 tests. Two-tailed p-
value <0.05 was considered statistically significant. 
 
Results 
 Fifty-seven males and 11 females were 
enrolled in the current study. Their ages ranged from 
29-57 years with mean of 45.09 years. Lab 
investigations in form of complete blood picture; liver 
function tests and lipid profile were recorded in Table 
1 where all data were expressed as mean ± SD. 
 As regards histopathological examination of 
liver biopsies, the mean values of Necroinflammation 
score was 9.17 ± 4.61. The frequencies of fibrosis 
stages 1-3 and 4–5 were 50 %, each. The frequencies 
of mild and moderate liver steatosis were 70.58% and 
29.42% respectively as shown in Table 1. 
Table 1: The demographic, clinical and biochemical data of the 
studied subjects. The data were expressed as mean ± SD. 
Variables  Results 
Age 45.09 ± 6.07 
Sex       
             Males no (%)  
             Females no (%) 
 
57 (83.8) 
11 (16.2) 
AST,  IU/dl 53.63 ± 20.13 
ALT,  IU/dl 70.83 ± 24.33 
GGT,  IU/dl 45.70 ± 6.46 
PLT 197340.0 ± 26090.06 
CHOL,  mg/dl 299.57 ± 72.87 
TRIG, mg/dl 199.06 ± 35.07 
LDL, mg/dl 123.45 ± 27.59 
HDL, mg/dl 53.50 ± 8.55 
PC, % 92.28 ± 14.59 
INR 0.95 ± 0.63 
ALB, gm/dl 4.62 ± 4.41 
PV, mm 13.14 ± 0.86 
Schistosomiasis: 
               Yes no (%)   
               No no (%)   
 
35 (51.5) 
33 (48.5) 
Necroinflammation score 9.17 ± 4.61 
Grades of fibrosis: 
                          1-3 no (%)   
                           4-6 no (%) 
 
34 (50) 
34 (50) 
Liver steatosis    
                          Mild (%) 
                          Moderate (%) 
 
48 (70.58) 
20 (29.42) 
 
Aspartate transaminase (AST), Alanine transaminase; (ALT),  Gamma glutamyl 
transaminase (GGT); Platelets (PLT); Hemoglobin (HGB); White blood cells (WBC); 
Cholesterol (CHOL); Triglycerides (TRIG); Low density lipoprotein (LDL); High density 
lipoprotein (HDL); Prothrombin concentration (PC); international normalization ratio (INR); 
Albumin (ALB); Portal vein (PV). 
 
 Comparison between group 1  patients  with 
grades of liver fibrosis from 0-3 and those group 2 
with grades from 4-6 revealed that the group 2 had 
higher mean values of portal vein diameter and higher 
mean values of Necroinflammation score. Both 
differences were highly significant (p<0.0001). 
Although group 2 had higher mean values of age and 
lipid profile than group 1, these differences did not 
reach the significant value.  
Table 2: Comparison between two groups of patients as 
regards laboratory investigations. 
Variables  F0-F3 
N=34 
F4-F6 
N=34 
T test P 
value 
Age 44.56 ± 6.03 45.58 ± 6.12 0.834 0.406 
AST, IU/dl 53.29 ± 20.97 53.94 ± 19.52 0.161 0.873 
ALT, IU/dl 70.54 ± 24.68 71.10 ± 24.24 0.113 0.910 
GGT, IU/dl 46.10 ± 5.95 45.33 ± 6.93 0.599 0.550 
PLT 198210 ± 27285 196540 ± 25176 0.318 0.751 
CHOL, mg/dl 294.10 ± 77.09 304.62 ± 69.11 0.719 0.474 
TRIG, mg/dl 195.37 ± 34.32 202.46 ± 35.75 1.010 0.315 
LDL, mg/dl 121.75 ± 24.29 125.02 ± 30.46 0.590 0.556 
HDL, mg/dl 52.88 ± 8.56 54.08 ± 8.57 0.701 0.485 
PC % 90.08 ± 1.566 94.31 ± 13.35 1.455 0.149 
INR 0.87 ± 0.15 1.03 ± 0.86 1.228 0.223 
ALB, mgldl 4.5 ± 0.75 4.21 ± 0.55 .967 0.336 
AST, IU/dl 12.80 ± 0.82 13.45 ± 0.80 4.021 0.000* 
Necroinflammation 
score 
5.29 ± 3.69 12.75 ± 1.25 
-13.750 0.000* 
ATX, ng/ml 71.22 ± 39.33 54.82 ± 31.43 1.899 0.062 
Aspartate transaminase (AST), Alanine transaminase;(ALT),  Gamma glutamyl 
transaminase (GGT);Platelets (PLT); Hemoglobin (HGB); White blod cells (WBC); 
Cholesterol (CHOL); Triglycerides (TRIG); Low density lipoprotein (LDL); High density 
lipoprotein (HDL); Prothrombin concentration (PC); International normalization ratio (INR); 
Albumin (ALB); Portal vein (PV); Autotoxin (ATX).*:p value is significant. 
 
 The mean values of ATX in all studied 
patients with chronic HCV infection was 63.02 ± 
36.29, ranged from 21.80 to 134.52 ng/ml while that of 
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healthy controls was 76.6 ± 25.06  ranged from 40.72 
to110.03 ng/ml without any significant difference. 
 Surprisingly, mean values of ATX were higher 
among patients with group 1 but it did not reach the 
significant level as shown in Table 2 and Fig. 1. 
Table 3: Comparison between males and females as regards 
serum ATX values among different grades of fibrosis. 
 
Grades of fibrosis  Males 
 
N=57 
Females 
N=11 
Grade 1 82.51 ± 36.88 62.30 ± 26.99 
Grade 2 70.40 ± 37.62 43.68 ± 5.17 
Grade 3 74.43 ± 55.61 33.14 ± 0.00 
Grade 4 48.67 ± 29.05 57.59 ± 31.42 
Grade 5 64.05 ± 36.67 43.37 ± 23.10 
Grade 6 41.67 ± 0.00 0.00 
F test  1.236 0.441 
P value 0.306 0.776 
 
 Pattern of ATX expression in males and 
females were demonstrated in Table 3, it was found 
that the highest mean values were found in grade 1 
fibrosis among both males and females. In each group 
of them, the differences between mean values of ATX 
among different grades of liver fibrosis were 
insignificant. It is also noticed that the mean values of 
ATX were higher among men than in women in 
different grades of fibrosis except grade 4 as shown in 
Table 3, Fig. 2, and Fig. 3. 
 
Figure 1: Mean values of ATX in studied groups of patients and 
controls. 
  
 The correlation between values of ATX and 
values of all studied parameters as that of blood 
picture; liver function tests; lipid profile; 
Necroinflammation score; grades of liver fibrosis 
revealed that  ATX was not correlated to any of these 
parameters. 
 
Figure 2: Mean values of ATX among males in different grades of 
fibrosis. 
 
 
Figure 3: Mean values of ATX among females in different grades of 
fibrosis. 
 
Discussion 
 It was found that ATX is not a diagnostic 
marker for liver fibrosis among studied patients with 
chronic HCV infection in the current study. These 
findings disagree with that of previous studies as 
Nakagawa and his colleagues, who concluded that 
serum ATX level  was correlated significantly with liver 
stiffness, a novel reliable marker of liver fibrosis, being 
the second-best parameter in male (AUROC, 0.799) 
and in female (AUROC, 0.876) for prediction of 
significant fibrosis, and the best parameter in male 
(AUROC, 0.863) and the third-best parameter in 
female (AUROC, 0.872) for prediction of cirrhosis, 
both of which were judged by liver stiffness [18]. In an 
experimental study, Watanabe and his colleagues 
suggested that Plasma LPA level and serum ATX 
activity are increased in various liver injuries in 
relation to their severity. At the same time, they 
recommended that whether increased ATX and LPA 
in the blood in liver injury is simply a result or also a 
cause of the injury should be further clarified [13].  
 Several questions concerning circulating ATX 
remain to be answered, including its tissue origin and 
metabolic fate, although recent evidence indicates 
that ATX is rapidly cleared from the circulation by liver 
sinusoidal endothelial cells [19]. Circulating ATX and 
LPA, of course, do not reflect the levels in intercellular 
spaces, since many different cell types produce ATX 
locally while the LPC substrate level in interstitial 
fluids is much lower than that in plasma. Another key 
question concerns how ATX activity is regulated under 
(patho) physiological conditions. Interestingly, ATX 
binds to activated lymphocytes and platelets in an 
integrin-dependent manner, which could lead to 
altered catalytic activity and serve as a mechanism for 
localized LPA production at sites of inflammation and 
injury. Our different findings may be refereed to 
genetic variation between the studied Egyptian 
population and other foreign patients in previous 
studies. The human ATX gene is organized in 27 
exons, and three alternative splicing isoforms of ATX, 
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named a, b, and c, have been reported [20]. 
Compared to the isoform b, the isoform a contains a 
52 residue-insertion (exon 12) in the catalytic domain, 
and the isoform c contains a 25-residue insertion 
(exon 21) close to the nuclease-like domain. Li and 
his colleagues confirmed that the activation of PKR, -
c-Jun N-terminal kinase JNK, and p38 mitogen 
activated protein kinase MAPK was required for the 
ATX induction. The LPS-induced ATX in THP-1 cells 
was characterized as the b isoform [21]. So that 
molecular basis for ATX serum expression may be 
changed between different populations. Hepatic 
schistosomiasis among Egyptian patients with chronic 
HCV may be another contributing factor in 
contradiction of our findings.  in the same context, it 
was proved that MAPKs are pivotal transmitters of 
extracellular signals such as hormones, cytokines, 
growth factors, and various environmental stress 
signals [22]. The MAPK family has three major 
subfamilies: ERK, P38, and JNK, and the P38 and 
JNK pathways are involved in hepatic satellite cells  
(HSC) transformation [23] and in the regulation of the 
complex life cycle and host-parasite interactions 
of schistosomiasis. While schistosomiasis is 
associated with an imbalance in T helper 1 (Th1)/Th2 
cytokines [24], differentiation of CD4+ T cells into Th1 
or Th2 lymphocyte population depends to a great 
extent upon the relative abundance of various 
cytokines during the priming of the antigen-specific 
lymphocyte population by antigen-presenting cells [25, 
26]. Collectively, different genetic predisposition; 
different environmental stress and co morbid added 
schistosomiasis, all may share in different pattern of 
immune expression that may reflect on serum ATX 
expression. 
 What mechanism responsible for increased 
plasma LPA and serum ATX activity in liver fibrosis? 
Factors involved with increasing serum ATX activity 
are likely primary because plasma LPA is essentially 
regulated by ATX [13] To explain increased serum 
ATX activity, two possibilities should be considered 
(although the origin and fate of serum ATX have not 
been fully elucidated): increased ATX production as a 
result of liver fibrosis or reduction in ATX clearance. In 
carbon tetrachloride-induced fibrotic rat livers, ATX 
mRNA expression was unaltered [13], i.e., production 
was not increased. Increased serum ATX activity was 
observed in 70% hepatectomized rats, as early as 
three hours post-surgery, and maintained for 24 h 
[13]. These findings suggest that increased serum 
ATX activity may be caused by a reduction in 
clearance. As such, the liver may not be the major site 
of ATX production, but the site of ATX clearance. In 
agreement, ATX was subsequently shown to be 
cleared from the circulation within minutes, taken up, 
and degraded in liver sinusoidal endothelial cells [18]. 
During the process of liver fibrosis, liver sinusoidal 
endothelial cells are known to undergo phenotypic 
changes with a loss of various receptors and 
sinusoidal endothelial fenestrae causing the 
capillarization of the sinusoids, thereby impairing the 
uptake of various substances. 
 Although previous in vitro findings have 
suggested a link between LPA and liver fibrosis in 
vivo, whether LPA plays a primary role in the 
Pathogenesis of liver fibrosis has remained uncertain. 
No phenotypic changes in livers of LPA receptor-
deficient mice have been demonstrated [27]. No 
modulations in liver fibrosis have so far been reported 
in these mice after liver injury. Of note, previous 
evidence has demonstrated relatively low gene 
expression of LPA receptors in Liver [28], suggesting 
that the roles of LPA may be limited in liver fibrosis. 
 In the current study we measured serum ATX 
not LPA because it was suggested that LPA can 
increase markedly after sample preparation unless 
temperature is strictly controlled [29]. This finding may 
result from the presence of synthetic ATX and its 
substrate lysophosphatidyl choline that can lead to 
abundant production of LPA in plasma [29]. Second, 
LPA is released from platelets, among other sources, 
and LPA should be measured in plasma to evaluate 
its clinical significance [30]. On the other hand, ATX 
activity can be measured in serum and is temperature 
stable [31]. 
 Nakagawa and his colleagues talked about 
gender bias of ATX expression but they did not give 
us explanation about this bias. In the current study, 
we noticed that in both males and females the 
differences between mean values of ATX among 
different grades of liver fibrosis were insignificant. It is 
also noticed that the mean values of ATX were higher 
among men than in women in different grades of 
fibrosis except grade 4 fibrosis. Gender bias of ATX 
may be referred to hormonal effects as it may be used 
as a marker for ovarian cancer [32]. 
 ATX was originally discovered in conditioned 
medium from A2058 human melanoma cell cultures 
and was characterized as a stimulator of cell migration 
[8]. Since then, ATX has been speculated to play a 
role in cancer invasion or metastasis as an autocrine 
motility factor [34]. However, the exact 
pathophysiological significanceof ATX remained 
unknown until the discovery of its lysoPLD activity [33, 
34] so, it was evident that ATX is not a specific marker 
for liver injury and this may be reflected on its serum 
expression in  relation to liver fibrosis. Moreover, we 
cannot depend on it in diagnosis or prediction of liver 
fibrosis. 
 In conclusion, autotaxin may be not a 
diagnostic marker for liver fibrosis in  Egyptian chronic 
HCV patients. Liver biopsy is recommended as the 
gold standard method for determining fibrosis. 
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